The EMA's financial juggling act
This article was originally published in Scrip
The European Medicines Agency is in the spotlight this week over the speed with which its former executive director, Thomas Lönngren, took up a post in the private sector. Public health groups have written to the European Commission claiming that the EMA did not follow EU procedures intended to prevent undue influence in the regulatory process, and should have imposed a "cooling off" period for Mr Lönngren to safeguard against potential conflicts of interest.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.